A team of scientists at UNMC and at Longevity Biotech, Inc., has demonstrated that disease-modifying neuroprotection could be attained by a novel drug candidate that changes immune responses.
 |
Scott Shandler, Ph.D. |
The results, published today in the Journal of Neuroscience, describe the prevention of nerve cell damage in a mouse model of Parkinson’s disease. Notably, the drug protected nerve cells that produce dopamine, the chemical responsible for agility and movement that is lost in Parkinson’s disease.
“The results are exciting as they provide a bridge between the immune system and nerve cell protection in Parkinson’s disease,” said Scott Shandler, Ph.D., co-founder and CEO of Longevity Biotech.
“The idea was birthed nearly a decade ago when specific types of circulating blood cells called lymphocytes were found to damage the types of nerve cells responsible for disease,” said Howard Gendelman, M.D., the Margaret R. Larson Professor and chair of the UNMC Department of Pharmacology and Experimental Neuroscience.
“The new Longevity Biotech drug (LBT-3627) was able to change the function of these cells from killing the nerve cells to protecting them. This is especially significant for the Nebraska team, as the mechanism parallels closely the human trials nearing completion for Parkinson’s patients.”
LBT-3627 is similar to the naturally occurring vasoactive intestinal peptide (VIP), a well-established anti-inflammatory peptide with beneficial effects across a variety of disorders. However, VIP is rapidly degraded by the body, and is unable to distinguish between its two naturally intended receptors (VPAC1 vs. VPAC2). These limitations have stymied prior translational success using VIP.
In contrast, LBT-3627 specifically targets VPAC2 and demonstrates impressive biological durability. In addition, LBT-3627 has the potential to be administered orally, Dr. Shandler said, which would further improve its clinical prospects and make it more beneficial to people with Parkinson’s disease.
Preclinical studies performed by the UNMC team, which included Katherine Olson and R. Lee Mosley, Ph.D., demonstrated that LBT-3627 could achieve up to 80 percent protection of dopamine-producing nerve cells in a mouse model of Parkinson’s disease. Furthermore, the immune transformation also affected primary scavenger cells called microglia cells that were found ultimately responsible for the neuroprotective activities observed that halted brain damage.
“The key finding in our study was that a specific white blood cell subset was produced as a consequence of LBT-3627 treatment and provided protection of dopamine producing nerve cells from being damaged,” Dr. Gendelman said. “The neurotoxic immune reaction was halted and LBT-3627 was able to prevent disease.”
Dr. Shandler said Longevity Biotech is currently progressing LBT-3627 through preclinical development and hopes to begin a Phase I clinical trial in humans by 2017.